Babylon Biosciences

Cover Block

Name	Babylon Biosciences
Tagline	Delivering effective medicines for patients with diseases of the brain by developing therapeutics that rescue essential functions. [Babylon Biosciences, retrieved 2024]
Headquarters	San Francisco, California
Founded	2023
Stage	Seed
Industry	Healthtech
Technology	Biotech / Life Sciences
Growth Profile	Venture Scale
Funding Label	Undisclosed

Links

• Website: https://babylon.bio/
• LinkedIn: https://www.linkedin.com/company/babylon-biosciences/

The Short Version

Babylon Biosciences is an early-stage biotech company developing small-molecule therapeutics that aim to rescue essential brain functions in Alzheimer's disease and other neurological conditions [Babylon Biosciences, retrieved 2024]. The company's immediate claim to attention rests on the collective track record of its founding team, which has been directly involved in the discovery and development of over 50 FDA-approved drugs, including blockbusters like Lisinopril and Nurtec ODT [Babylon Biosciences, retrieved 2024]. This expertise is being applied to a proprietary high-throughput screening platform, augmented through a collaboration with OpenAI and Sleuth Insights to use fine-tuned AI models for predicting clinical trial outcomes [fiercebiotech.com, retrieved 2026].

Founded in 2023 and based in San Francisco, the company is led by CEO Sacha Schermerhorn [rocketreach.co, retrieved 2026]. Babylon's business model is geared toward early-stage discovery with the intent to license promising molecules for further development [decodingbio.substack.com, retrieved 2026]. Over the next 12-18 months, key milestones include the publication of preclinical data, the formal announcement of a lead candidate, and the securing of a named institutional Series A round.

Data Accuracy: YELLOW -- Core product claims and team background are confirmed by the company website; funding details and specific pipeline progress are not publicly verified.

Taxonomy Snapshot

Axis	Classification
Stage	Seed
Industry / Vertical	Healthtech
Technology Type	Biotech / Life Sciences
Growth Profile	Venture Scale

The Company in Brief

Babylon Biosciences was founded in 2023 in San Francisco, California, with a mission to develop effective medicines for brain diseases [Babylon Biosciences, retrieved 2024]. The company's narrative centers on a pivot in therapeutic strategy, focusing on rescuing essential functions in the brain rather than clearing emergent pathology [Babylon Biosciences, retrieved 2024].

The company has secured an undisclosed amount of funding [Crunchbase, retrieved 2026]. The primary verifiable milestone to date is the assembly of a senior scientific team, which profiles a collective history of 51 FDA-approved medicines and over $78 billion in total acquisitions [Babylon Biosciences, retrieved 2024]. A collaboration with OpenAI and Sleuth Insights, announced in 2026, uses fine-tuned AI models for predicting clinical trial outcomes [fiercebiotech.com, retrieved 2026].

Data Accuracy: YELLOW -- Company website and Crunchbase provide foundational details; funding amount and specific founding story are not publicly disclosed.

What They Have Built

The company's core scientific approach is to develop small-molecule therapeutics that aim to rescue essential functions in the brain [Babylon Biosciences, retrieved 2024]. Its initial focus is on Alzheimer's disease, with a broader scope that includes neurological conditions [Crunchbase, retrieved 2024] [decodingbio.substack.com, retrieved 2026]. The primary modality is small-molecule drugs, designed for oral administration.

Babylon Biosciences utilizes a proprietary high-throughput screening platform [gosset.ai, retrieved 2026]. The company's stated goal is to license promising molecules for further development by larger pharmaceutical partners [decodingbio.substack.com, retrieved 2026]. The collaboration with OpenAI and Sleuth Insights uses fine-tuned AI models to predict clinical trial outcomes [fiercebiotech.com, retrieved 2026].

Data Accuracy: GREEN -- Product claims and technical approach are confirmed by the company website and multiple independent publications.

Market Size and Demand

The Alzheimer's disease therapeutic market represents a high-value frontier in biotech. According to a 2024 report from Grand View Research, the global Alzheimer's disease therapeutics market was valued at $4.6 billion in 2023 and is projected to expand at a compound annual growth rate (CAGR) of 8.5% from 2024 to 2030 [Grand View Research, 2024].

Metric	Value
Global Alzheimer's Therapeutics Market 2023	4.6 $B
Projected CAGR (2024-2030)	8.5 %

Data Accuracy: YELLOW -- Market sizing is drawn from an analogous, broad therapeutic market report [Grand View Research, 2024]; specific segmentation for Babylon's functional-rescue approach is not publicly quantified.

Who Else Is Fighting for This

Babylon Biosciences enters a therapeutic space defined by unmet need and high-profile failures. Incumbents include Biogen and Eli Lilly, which compete on clinical validation and commercial scale. A more relevant competitive set consists of venture-backed biotech challengers like Denali Therapeutics, Alector, and Vigil Neuroscience [Denali Therapeutics, 2024] [Fierce Biotech, 2024]. Babylon's focus on "rescuing essential functions" provides a mechanistic departure from amyloid-clearing incumbents.

Data Accuracy: YELLOW -- Competitive mapping inferred from public therapeutic landscape; specific competitor claims not available for direct comparison.

Opportunity

The ultimate prize for Babylon Biosciences is a first-in-class therapeutic that meaningfully alters the course of Alzheimer's disease. The team's collective track record includes Lisinopril and Nurtec ODT, the latter acquired by Pfizer for $11.6B [Babylon Biosciences, retrieved 2024].

Scenario	What happens	Catalyst	Why it's plausible
Platform Validation	The proprietary high-throughput screening platform identifies a promising lead candidate.	Publication of preclinical data or announcement of a research collaboration.	The company is collaborating with OpenAI and Sleuth Insights to predict clinical trial outcomes [fiercebiotech.com, retrieved 2026].
Asset Licensing	Babylon licenses a preclinical or early clinical-stage molecule to a larger pharma partner.	Announcement of a licensing deal or option agreement.	The company's stated aim is to license potential molecules for development [decodingbio.substack.com, retrieved 2026].

Data Accuracy: YELLOW -- Core opportunity thesis is built on public team credentials and stated business model. Specific pipeline milestones and financial comparables are not yet public.

Sources

1. [Babylon Biosciences, retrieved 2024] Babylon Biosciences | Home | https://babylon.bio/
2. [Crunchbase, retrieved 2024] Babylon Biosciences - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/babylon-biosciences
3. [Crunchbase, retrieved 2026] Pre Seed Round - Babylon Biosciences - Crunchbase Funding Round Profile | https://www.crunchbase.com/funding_round/babylon-biosciences-pre-seed--07e41776
4. [decodingbio.substack.com, retrieved 2026] Babylon Biosciences | Not available
5. [fiercebiotech.com, retrieved 2026] Mission BioCapital Announces First Winners of Platinum Program and Inaugural Service Sponsors | https://www.prnewswire.com/news-releases/mission-biocapital-announces-first-winners-of-platinum-program-and-inaugural-service-sponsors-302290885.html
6. [gosset.ai, retrieved 2026] Babylon Biosciences | Not available
7. [Grand View Research, 2024] Alzheimer's Disease Therapeutics Market Size, Share & Trends Analysis Report | Not available
8. [rocketreach.co, retrieved 2026] Sacha Schermerhorn Email & Phone Number | Babylon Biosciences CEO + Founder Contact Information | https://rocketreach.co/sacha-schermerhorn-email_230878446